A simpler diagnostic formula for screening nonalcoholic fatty liver disease |
| |
| Affiliation: | 1. Xi''an Medical University, Xi''an, China;2. The First Affiliated Hospital of Xi''an Medical University, Xi''an, China;3. Department of Gastroenterology, Xiangan Hospital Affiliated to Xiamen University, Xiamen, China;4. NAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China;5. School of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, China;6. Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China;7. Institute of Hepatology, Wenzhou Medical University, Wenzhou, China.;8. Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, Wenzhou 325000, China;1. Department of Pediatric Gastroenterology, the First Hospital, Jilin University, Changchun 130021, Jilin, China;2. Translational Medicine Research Institute, the First Hospital, Jilin University, Changchun 130021, Jilin, China;3. Department of Hepatology, the First Hospital, Jilin University, Changchun 130021, Jilin, China;1. ACT Pathology, The Canberra Hospital, Garran, ACT 2605, Australia;2. Australian National University Medical School, Garran, ACT 2605, Australia;3. College of Medicine Biology and Environment, Australian National University, Garran, ACT 2605, Australia;1. Biochemistry and Immunology, Lillebaelt Hospital, Denmark;2. Department of Regional Health Research, University of Southern Denmark, Denmark;3. OPEN, Odense Patient data Explorative Network, Odense University Hospital, Odense, Denmark;4. Department of Vascular Surgery, Lillebaelt Hospital, Kolding, Denmark |
| |
| Abstract: | ObjectiveTo increase the accuracy of non-invasive diagnosis of nonalcoholic fatty liver disease (NAFLD), clinical and laboratory NAFLD indicators were integrated into a diagnostic formula.MethodsA total of 141 patients with clinically diagnosed NAFLD and 30 healthy controls were enrolled. We collected case history, body weight, height and mass index (BMI), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transpeptidase, blood urea nitrogen and blood uric acid (UA), serum creatinine, plasma total cholesterol, triglyceride, low density lipoprotein, glycosylated hemoglobin, fasting plasma glucose, fasting insulin, ultrasonic tests, Fibroscans, and other data. Linear correlation, multiple linear regressions, and receiver operating characteristic (ROC) curve methods were used to process and analyze the collected data. The performance of Fibroscan and our diagnostic formula was compared in reference to the findings of liver biopsy.ResultsThe identified NAFLD diagnostic indices consisted of BMI, ALT, AST and UA. A regression formula was proposed as: CAP = 113.163 + 0.252 * ALT + 6.316 * BMI. Diagnosis of the area under the ROC curve was 0.927, the sensitivity was 87.68%, and specificity was 90%. The cutoff was 277.67 (p < 0.01). The accuracy of the NAFLD diagnosis with the proposed formula was significantly higher than FibroScan (82.6% vs 69.6%; p = 0.005).ConclusionsNAFLD diagnosis with the proposed formula demonstrated both high sensitivity and specificity, and its accuracy was significantly higher than FibroScan. This formula only utilized non-invasive clinical and laboratory findings and the calculation was simple. It can be conveniently used for clinical diagnosis of NAFLD. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
